Avant Diagnostics is a medical technology company at the
forefront of driving an evolution in the screening of ovarian cancer. Its focus
is centered on bringing to market innovative diagnostic tests based upon the
completion of the human genome sequencing project. The company endeavors in
developing a refined screening test for diagnosing ovarian cancer by way of
OvaDx – the market’s first large-panel biomarker screening test for this deadly
disease.
OvaDx® is considered to be an advanced diagnostic test that
measures the activation of the immune system in response to ovarian tumor cell
development. Patient sera are applied to OvaDx® microarrays which enable
binding between proteomic biomarkers in the patient samples and capture agents
on the microarrays. The microarrays are washed and scanned to produce a digital
readout for each serum sample, and the data are quantified and analyzed in
software to generate the test results.
Medical findings in genetic research offer extensive
opportunities for impacting both the diagnosis and treatment of critical
diseases. It focusses on identifying variations in specific genes in the
genome, variations which reveal individual characteristics, including the state
of the disease or its statistical characteristics. Tests of this nature that
detect diseases at early stages in their progression and thus offer different
options for earlier treatments resulting in better outcomes for the patient. As
an additional result, medical providers benefit by way of significant cost savings
by avoiding costly treatments traditionally reserved for cancer in its later
stages.
AVDX’s discovery path is a result of a decade of genetic and
physiological research. The company concentrates on capitalizing on the human
immune system for early detection. The result, OvaDx, delivers a large panel of
refined markers for high sensitivity. The company’s OvaDx markers and kits are
proprietary, include patented manufacturing technology, and an exclusive,
worldwide license. Upon FDA 510(k) clearance, Avant intends to sell or license
OvaDx®. Avant intends to utilize its public company stage to expand its
portfolio of diagnostic tests in the future.
For more information on the company, visit
www.avantdiagnostics.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment